Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of PTH134 in Post-menopausal Women

Inclusion Criteria: * Post-menopausal women osteoporotic/osteopenic with an additional risk factor 45 to 80 years old Exclusion Criteria: * Use of estrogen or hormone replacement therapy * Use of parathormone or parathormone fragments, calcitonin, aluminum supplements, within 12 months prior to first dose. * Use of bisphosphonates and strontium ranelate * Cancer or history of malignancy of any organ system * Any radiation therapy to the skeleton. * Any known clinically significant disease affecting calcium metabolism. Any history of metabolic disorders including Paget's disease, osteogenesis imperfecta, or osteomalacia. * History or clinical evidence of any impairment of thyroid function * Other protocol-defined inclusion/exclusion criteria apply.